United Therapeutics Co. (NASDAQ:UTHR) Stake Raised by APG Asset Management US Inc.

APG Asset Management US Inc. increased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 2.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,168 shares of the biotechnology company’s stock after buying an additional 282 shares during the quarter. APG Asset Management US Inc.’s holdings in United Therapeutics were worth $4,201,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in United Therapeutics by 6.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 164 shares during the period. UBS Group AG increased its stake in shares of United Therapeutics by 12.2% during the fourth quarter. UBS Group AG now owns 64,674 shares of the biotechnology company’s stock valued at $14,221,000 after acquiring an additional 7,020 shares during the period. Franklin Resources Inc. lifted its position in United Therapeutics by 355.8% in the fourth quarter. Franklin Resources Inc. now owns 49,851 shares of the biotechnology company’s stock worth $10,962,000 after purchasing an additional 38,915 shares during the period. Hsbc Holdings PLC boosted its stake in United Therapeutics by 6.1% during the 4th quarter. Hsbc Holdings PLC now owns 94,693 shares of the biotechnology company’s stock valued at $20,811,000 after purchasing an additional 5,416 shares in the last quarter. Finally, TD Asset Management Inc increased its position in shares of United Therapeutics by 1,066.4% during the 4th quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after purchasing an additional 75,839 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on UTHR. Jefferies Financial Group upped their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday. LADENBURG THALM/SH SH cut shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Company increased their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Trading Down 0.5 %

Shares of UTHR opened at $357.72 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $366.08. The firm has a market cap of $15.91 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 1.29 and a beta of 0.57. The business’s fifty day moving average is $341.49 and its 200-day moving average is $294.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period last year, the business earned $5.24 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.84 EPS for the current fiscal year.

Insider Activity

In related news, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO James Edgemond sold 7,785 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. Insiders sold 111,252 shares of company stock valued at $36,939,427 over the last quarter. 12.50% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.